The superiority of CD31 in terms of sensitivity and specificity for endothelial cells is well recognized, with reported sensitivity rates of 80 percent versus 62 percent in vasoformative and poorly vasoformative angiosarcomas, respectively. The gene discussed is PECAM1; the disease is angiosarcoma.